Search
for
Sort by
Research 31–60 of 139
- Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
- Teriflunomide in multiple sclerosis: an update
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract
- Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
- Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Current and future pharmacotherapy for alopecia areata
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
- Cytokine-targeted treatment in alopecia areata - new possibilities?
- Janus Kinase inhibitors in dermatology: a review
- 608 A clinical study to test the efficacy of VB1953 in clindamycin non-responder acne patients with antibiotic-resistant P. acnes
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Pharmacotherapy of alopecia areata
- Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches